Close

Glycoprotein Iib/IIIa

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. It recognizes the sequence R-G-D in a wide array of ligands. It recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial cell surface.
  • CAR Vector Products

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAART-LX071 Anti-Glycoprotein Iib/IIIa (X8LX149) h(CD28-CD3ζ) CAART, pCDCAAR1 Human X8LX149 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX072 Anti-Glycoprotein Iib/IIIa (PAC-1) h(CD28-CD3ζ) CAART, pCDCAAR1 Human PAC-1 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX073 Anti-Glycoprotein Iib/IIIa (X8LX147) h(CD28-CD3ζ) CAART, pCDCAAR1 Human X8LX147 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX074 Anti-Glycoprotein Iib/IIIa (X8LX148) h(CD28-CD3ζ) CAART, pCDCAAR1 Human X8LX148 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX075 Anti-Glycoprotein Iib/IIIa (X8LX150) h(CD28-CD3ζ) CAART, pCDCAAR1 Human X8LX150 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX076 Anti-Glycoprotein Iib/IIIa (X8LX146) h(CD28-CD3ζ) CAART, pCDCAAR1 Human X8LX146 Mouse scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX077 Anti-Glycoprotein Iib/IIIa (34D10) h(CD28-CD3ζ) CAART, pCDCAAR1 Human 34D10 Humanized scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX078 Anti-Glycoprotein Iib/IIIa (X8LX149) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Human X8LX149 Human scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX079 Anti-Glycoprotein Iib/IIIa (PAC-1) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Human PAC-1 Human scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX080 Anti-Glycoprotein Iib/IIIa (X8LX147) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Human X8LX147 Human scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX081 Anti-Glycoprotein Iib/IIIa (X8LX148) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Human X8LX148 Human scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX082 Anti-Glycoprotein Iib/IIIa (X8LX150) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Human X8LX150 Human scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX083 Anti-Glycoprotein Iib/IIIa (X8LX146) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Human X8LX146 Mouse scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX084 Anti-Glycoprotein Iib/IIIa (34D10) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Human 34D10 Humanized scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.